View Document Preview and Link Document Date: 2010-08-31 18:48:51 Open Document File Size: 378,61 KB Share Result on Facebook
City Sydney / / Company Ge / Vertex Pharmaceuticals / Merck / Hepatitis Interventional Therapy Group / C. Hepatitis Interventional Therapy Group / International Hepatitis Interventional Therapy Group / non-A non-B / / Country Japan / United States / Australia / / Event FDA Phase / / Facility Westmead Hospital / Westmead Millennium Institute / SEIB Sydney Institute / / IndustryTerm shared injecting equipment / treatment protocols / HCV treatment / Hepatitis C treatment / / MedicalCondition HCV RNA six / chronic non-A / nonB viral hepatitis / HIV / non-B hepatitis / HCV genotype 1 / chronic hep C. Hepatology / cirrhosis / Hepatitis C / recently acquired hepatitis C / C virus epidemic / HCV-associated cirrhosis / infectious agent / chronic HCV infection / infections / transfusion-acquired hepatitis / HCV genotype / insulin resistance / disease / hepatocellular carcinoma / Background Hepatitis C / future hepatitis C / chronic HCV / HIV/hepatitis C / acute HCV infections / hepatitis C-related fibrosis / C infection / HCV / liver fibrosis / virus infection / Infectious Diseases / infection / chronic infection / chronic hepatitis C / fibrosis / / MedicalTreatment liver transplant / antiviral therapy / treatment protocols / adjuvant therapy / / Organization SEIB Sydney Institute / Storr Liver Unit / World Health Organization / Westmead Millennium Institute / National Centre / Westmead Hospital / / Person C. Ann N Y Acad Sci / / Product pioglitazone / polyethylene glycol / Peginterferon / ribavirin / treatment-naïve / IL28B / / Technology alpha / ultrasound / cloning / existing treatment protocols / genotype / / URL www.cidmpublichealth.org / / SocialTag 
THE BROAD STREET PUMP Brave New World? Recent developments in Hepatitis C treatment Mark Douglas Summary